Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila

Indian drug maker to get know-how from Gilead Sciences Inc, to manufacture the API for Remdesivir, make the finished product and market it in 127 countries, including India

After Cipla, Jubilant Lifesciences and Hetero Labs, Gilead Sciences Inc. has now signed a non-exclusive licensing agreement with Cadila Healthcare Ltd (Zydus Cadila) for manufacturing and distribution of its investigational drug Remdesivir for treating Covid-19.

After being issued an Emergency Use Authorization by the US Food and Drug Administration (FDA) for Remdesivir to treat patients suffering from severe symptoms of novel coronavirus (Covid-19), Gilead has entered India through such agreements with domestic players.

Zydus, which is also involved in developing a vaccine for coronavirus, will now also get to manufacture and distribute Remdesivir. The Indian drug maker will receive the